Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent ...
Cardiol Therapeutics completes MAvERIC Phase II study for recurrent pericarditis, showing marked reductions in pain and inflammation at 8 weeks. Full clinical data to be presented at the American Heart Association Scientific Sessions 2024.
Related Clinical Trials
Reference News
Cardiol Therapeutics Inc. completed enrollment of 100 patients in ARCHER, a Phase II trial evaluating CardiolRxTM for myocardial recovery in acute myocarditis. The trial, published in ESC Heart Failure, aims to assess safety, tolerability, and impact on myocardial recovery using cardiac MRI measures. Acute myocarditis, caused by viral or bacterial infections, drugs, and vaccines, lacks FDA-approved treatments and has significant health and economic burdens.
Cardiol Therapeutics has enrolled 100 patients in its Phase II ARCHER trial evaluating CardiolRx™ for acute myocarditis, with topline results expected early next year. The trial aims to assess CardiolRx™'s impact on myocardial recovery and safety in acute myocarditis patients, complementing data from the MAvERIC Phase II study in recurrent pericarditis.
Cardiol Therapeutics completes MAvERIC Phase II study in recurrent pericarditis; results to be presented at American Heart Association Scientific Sessions 2024. The study, led by Dr. S. Allen Luis, demonstrated CardiolRx™'s efficacy in reducing pericarditis pain and inflammation. Full clinical data will be reported in an oral presentation on November 18, 2024.
Cardiol Therapeutics completes target patient enrollment for Phase II ARCHER trial evaluating CardiolRx™ in acute myocarditis, aiming to assess safety, tolerability, and impact on myocardial recovery with topline results expected early next year.
Cardiol Therapeutics completes MAvERIC Phase II study for recurrent pericarditis, showing marked reductions in pain and inflammation at 8 weeks. Full clinical data to be presented at the American Heart Association Scientific Sessions 2024.
Cardiol Therapeutics announces completion of target patient enrollment in Phase II ARCHER trial evaluating CardiolRx™ for acute myocarditis, with topline results expected early next year. The trial aims to assess CardiolRx™'s impact on myocardial recovery and complements ongoing MAvERIC Phase II study in recurrent pericarditis, results to be presented at the American Heart Association Scientific Sessions 2024.
Cardiol Therapeutics is developing CardiolRx™, a cannabidiol oral solution for heart disease, with Phase II trials for recurrent pericarditis and acute myocarditis. The company also aims to develop CRD-38, a subcutaneous cannabidiol formulation for heart failure, and has a strong financial position and experienced leadership.
Cardiol Therapeutics to present Phase II MAvERIC-Pilot study data on CardiolRx™ for recurrent pericarditis at the American Heart Association Scientific Sessions 2024, showcasing marked reductions in pain and inflammation.
Cardiol Therapeutics to present Phase II MAvERIC-Pilot study data on CardiolRx™ for pericarditis at American Heart Association Scientific Sessions on Nov 18, 2024. The study showed significant symptom reduction at 8 weeks and will support a Phase III trial. The company also received a Buy rating from Roth/MKM with a $10.00 price target and has sufficient cash reserves to fund operations into 2026.
Switch Market flag for country-specific data. Right-click on the chart for more options. Use up/down arrows to navigate symbols.